10-K/A: DBV Technologies Details Share Structure, Governance, and Executive Compensation in Amended 10-K Filing

DBV Technologies provides an overview of its ordinary shares, American Depositary Shares, corporate governance practices, and executive compensation in its amended 10-K filing.

Summary

• DBV Technologies S.A., a French socit anonyme, has filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
• As of December 31, 2024, the company's outstanding share capital consisted of 102,847,501 issued ordinary shares with a nominal value of 0.10 per share.
• The company has American Depositary Shares (ADSs) listed on the Nasdaq Capital Market, each representing five ordinary shares.
• The company's corporate purpose includes developing innovative medical products, particularly drugs, diagnostics, and treatments.
• Directors are designated at a shareholders' ordinary general meeting for a three-year term.
• The board of directors can only deliberate if at least half of the directors attend the meeting.
• The company may only distribute dividends out of its distributable profits, with a legal reserve requirement of 5% of unconsolidated net profit each year until the reserve equals 10% of the issued and outstanding share capital.
• Shareholders have preferential subscription rights to subscribe for new shares or other securities giving rights to acquire additional shares on a pro rata basis.
• The company's by-laws and French corporate law contain provisions that could make it more difficult for a third party to acquire the company.
• The company has adopted a Code of Ethics and Business Conduct applicable to all directors, officers, and employees.
• The aggregate market value of voting and non-voting common equity held by non-affiliates on June 30, 2024, was $84.2 million.
• As of April 15, 2025, the company had 136,948,872 ordinary shares outstanding.
• The company completed a $307 million PIPE financing in April 2025.
• The company's executive compensation program includes base salary, annual performance-based incentives, and long-term incentive compensation.
• The company's Audit Committee has responsibility for appointing, setting compensation of and overseeing the work of the independent registered public accounting firm.

Sentiment

Score: 6

Explanation: The document is primarily descriptive, outlining the company's structure, governance, and compensation practices. The sentiment is neutral, with no strong positive or negative indicators.

Positives

• The company has a clear corporate purpose focused on developing innovative medical products.
• The company adheres to gender diversity requirements for its board of directors.
• The company has a Code of Ethics and Business Conduct for its directors, officers, and employees.
• The company has a related-party transaction policy to ensure transparency and fairness.
• The company has a clawback policy to recoup compensation in case of financial restatements due to misconduct.
• The company completed a $307 million PIPE financing in April 2025.

Negatives

• The company's by-laws and French corporate law contain provisions that could make it more difficult for a third party to acquire the company, potentially limiting shareholder value.
• The company's Audit Committee may only have an advisory role on matters requiring approval of the Board of Directors under French law and can only make recommendations to the Board of Directors on such matters.

Risks

• Change in control provisions could deter potential acquirers, even if an acquisition would benefit shareholders.
• The company's reliance on key personnel and the potential loss of these individuals could negatively impact operations.
• The company's ability to protect its intellectual property and maintain its competitive advantage is crucial for its success.
• The company's ability to obtain regulatory approvals for its products is uncertain and could impact its future prospects.
• The company's ability to raise additional capital in the future is not guaranteed and could impact its ability to fund its operations.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the general corporate purpose of developing innovative medical products.

Industry Context

DBV Technologies operates in the competitive biopharmaceutical industry, focusing on developing innovative medical products. The company benchmarks against similarly sized U.S. and French biopharmaceutical companies to offer competitive compensation packages.

Comparison to Industry Standards

• The document mentions benchmarking against similarly sized U.S. and French biopharmaceutical companies for compensation purposes.
• However, it does not provide specific details on comparable companies or projects.
• The document does not provide specific details on global benchmarks.

Related Party Transactions

• Entities affiliated with Baker Bros. Advisors LP and Bpifrance Participations S.A. participated in the April 2025 PIPE financing.
• DBV Technologies has entered into a registration rights agreement with entities affiliated with Baker Bros. Advisors LP.
• DBV Technologies has entered into employment agreements with its executive officers.

Stakeholder Impact

• Shareholders are impacted by the company's governance structure, compensation practices, and related-party transactions.
• Employees are impacted by the company's compensation and benefits policies.
• Customers and patients are impacted by the company's ability to develop innovative medical products.
• The company's financial performance and ability to execute its strategy impact all stakeholders.

Next Steps

• The company will continue to develop innovative medical products.
• The company will continue to comply with applicable laws and regulations.
• The company will continue to monitor and manage its risks.
• The company anticipates filing a registration statement with the SEC registering the resale of up to 289,013,065 ordinary shares issued in the 2025 PIPE financing.

Key Dates

Keywords

DBV Technologies, ordinary shares, American Depositary Shares, corporate governance, executive compensation, shareholder rights, board of directors, audit committee, PIPE financing, related party transactions